# John Lunec

List of Publications by Year
in descending order



| 63 | 3,144 | 136740 | 155451 |
|---|---|---|---|
| papers | citations | 32 h-index | 55 g-index |

| 63 | 63 | 63 | 4131 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer. Nature Medicine, 1996, 2, 912-917. | 15.2 | 255 |
| 2 | Quantification of MYCN, DDX1, and NAG Gene Copy Number in Neuroblastoma Using a Real-Time Quantitative PCR Assay. Modern Pathology, 2002, 15, 159-166. | 2.9 | 167 |
| 3 | The p53 pathway and its inactivation in neuroblastoma. Cancer Letters, 2003, 197, 93-98. | 3.2 | 159 |
| 4 | High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clinical Cancer Research, 2010, 16, 1108-1118. | 3.2 | 143 |
| 5 | Small-Molecule Inhibitors of the MDM2-p53 Proteinâ^'Protein Interaction Based on an Isoindolinone Scaffold. Journal of Medicinal Chemistry, 2006, 49, 6209-6221. | 2.9 | 136 |
| 6 | Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Proteinâ^'Protein Interaction: Structureâ^'Activity Studies Leading to Improved Potency. Journal of Medicinal Chemistry, 2011, 54, 1233-1243. | 2.9 | 130 |
| 7 | p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma. Cancer Research, 2010, 70, 1377-1388. | 0.4 | 118 |
| 8 | Increased Frequency of Aberrations in the p53/MDM2/p14ARF Pathway in Neuroblastoma Cell Lines Established at Relapse. Cancer Research, 2006, 66, 2138-2145. | 0.4 | 113 |
| 9 | Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from britain. Hepatology, 1992, 16, 1362-1366. | 3.6 | 104 |
| 10 | MYCN oncoprotein targets and their therapeutic potential. Cancer Letters, 2010, 293, 144-157. | 3.2 | 92 |
| 11 | Isoindolinone-based inhibitors of the MDM2â€“p53 proteinâ€“protein interaction. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1515-1520. | 1.0 | 89 |
| 12 | p53 Cellular Localization and Function in Neuroblastoma. American Journal of Pathology, 2001, 158, 2067-2077. | 1.9 | 86 |
| 13 | Cultured Human Melanocytes Respond to MSH Peptides and ACTH. Pigment Cell & Melanoma Research, 1994, 7, 217-221. | 4.0 | 77 |
| 14 | Non-glucose metabolism in cancer cellsâ€”is it all in the fat?. Cancer and Metastasis Reviews, 2012, 31, 689-698. | 2.7 | 72 |
| 15 | The MYCN oncoprotein as a drug development target. Cancer Letters, 2003, 197, 125-130. | 3.2 | 66 |
| 16 | Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget, 2015, 6, 10207-10221. | 0.8 | 64 |
| 17 | Of dogs and men: Comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma. Pediatric Blood and Cancer, 2012, 58, 327-333. | 0.8 | 57 |
| 18 | NovelERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma. Genes Chromosomes and Cancer, 2001, 31, 288-294. | 1.5 | 53 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer. Oncotarget, 2016, 7, 40115-40134. | 0.8 | 53 |
| 20 | Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clinical Cancer Research, 2003, 9, 3338-44. | 3.2 | 48 |
| 21 | Heat shock factor-1 modulates p53 activity in the transcriptional response to DNA damage. Nucleic Acids Research, 2009, 37, 2962-2973. | 6.5 | 47 |
| 22 | Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma. British Journal of Cancer, 2018, 118, 495-508. | 2.9 | 47 |
| 23 | Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors. Genes Chromosomes and Cancer, 2002, 34, 428-436. | 1.5 | 46 |
| 24 | The Role of MYCN in the Failure of MYCN Amplified Neuroblastoma Cell Lines to G1 Arrest After DNA Damage. Cell Cycle, 2006, 5, 2639-2647. | 1.3 | 44 |
| 25 | Cell Cycle Regulation Targets of MYCN Identified by Gene Expression Microarrays. Cell Cycle, 2007, 6, 1249-1256. | 1.3 | 44 |
| 26 | Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells. Prostate, 2007, 67, 900-906. | 1.2 | 44 |
| 27 | p53 is Nuclear and Functional in Both Undifferentiated and Differentiated Neuroblastoma. Cell Cycle, 2007, 6, 2685-2696. | 1.3 | 40 |
| 28 | A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma. Clinical Cancer Research, 2011, 17, 792-804. | 3.2 | 39 |
| 29 | Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell lines. , 1998, 23, 116-122. | | 36 |
| 30 | Genes co-amplified with MYCN in neuroblastoma: silent passengers or co-determinants of phenotype?. Cancer Letters, 2003, 197, 81-86. | 3.2 | 36 |
| 31 | High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays. Cancer Genetics and Cytogenetics, 2007, 172, 127-138. | 1.0 | 36 |
| 32 | MDM2-p53 proteinâ€“protein interaction inhibitors: A-ring substituted isoindolinones. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5916-9. | 1.0 | 36 |
| 33 | Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner. Molecular Cancer Therapeutics, 2016, 15, 379-391. | 1.9 | 36 |
| 34 | The neuroblastoma amplified gene, NAG : genomic structure and characterisation of the 7.3 kb transcript predominantly expressed in neuroblastoma. Gene, 2003, 307, 1-11. | 1.0 | 34 |
| 35 | Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer. Clinical Cancer Research, 2003, 9, 2576-82. | 3.2 | 34 |
| 36 | PARP1 expression, activity andex vivosensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia. Oncotarget, 2015, 6, 43978-43991. | 0.8 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Comparative Assessment Expression of the Inhibitor of Growth 1 Gene (ING1) in Normal and Neoplastic Tissues. Hybridoma, 2002, 21, 1-10. | 0.6 | 30 |
| 38 | Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Proteinâ€"Protein Interaction. Journal of Medicinal Chemistry, 2021, 64, 4071-4088. | 2.9 | 30 |
| 39 | Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer. Oncotarget, 2017, 8, 69779-69796. | 0.8 | 27 |
| 40 | ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma. Cancers, 2019, 11, 3. | 1.7 | 26 |
| 41 | Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. Oncology Reports, 2008, 19, 825-30. | 1.2 | 26 |
| 42 | Genomic organisation of the human MDM2 oncogene and relationship to its alternatively spliced mRNAs. Gene, 2004, 338, 217-223. | 1.0 | 24 |
| 43 | No Evidence for Correlation of DDX1 Gene Amplification With Improved Survival Probability in Patients With MYCN-Amplified Neuroblastomas. Journal of Clinical Oncology, 2005, 23, 3167-3168. | 0.8 | 24 |
| 44 | Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2â€"p53 and MDMXâ€"p53 proteinâ€"protein interactions. MedChemComm, 2013, 4, 1297. | 3.5 | 24 |
| 45 | Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. International Journal of Cancer, 2019, 144, 3146-3159. | 2.3 | 23 |
| 46 | High level expression of the multidrug resistance (MDRI) gene in the normal bladder urothelium: a potential involvement in protection against carcinogens?. Carcinogenesis, 1996, 17, 601-604. | 1.3 | 22 |
| 47 | TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation. Oncotarget, 2016, 7, 46203-46218. | 0.8 | 22 |
| 48 | Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers. Biomolecules, 2020, 10, 1474. | 1.8 | 19 |
| 49 | Characterisation of a novel p53 down-regulated promoter in intron 3 of the human MDM2 oncogene. Gene, 2005, 361, 112-118. | 1.0 | 15 |
| 50 | Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells. Haematologica, 2019, 104, 2429-2442. | 1.7 | 15 |
| 51 | Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. Oncology Reports, 2008, , . | 1.2 | 14 |
| 52 | Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Nonâ€"Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker. Clinical Lung Cancer, 2015, 16, 348-357. | 1.1 | 14 |
| 53 | Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression. Cell Cycle, 2011, 10, 3778-3787. | 1.3 | 12 |
| 54 | Searching for Dual Inhibitors of the <scp>MDM</scp>2â€p53 and <scp>MDMX</scp>â€p53 Proteinâ€"Protein Interaction by a Scaffoldâ€Hopping Approach. Chemical Biology and Drug Design, 2015, 86, 180-189. | 1.5 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Molecular pathology and potential therapeutic targets in soft-tissue sarcoma. Expert Review of Anticancer Therapy, 2008, 8, 939-948. | 1.1 | 9 |
| 56 | Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor. Cancer Medicine, 2018, 7, 4744-4754. | 1.3 | 9 |
| 57 | TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response. Cancer Cell International, 2019, 19, 53. | 1.8 | 9 |
| 58 | HCV Activates Somatic L1 Retrotranspositionâ€"A Potential Hepatocarcinogenesis Pathway. Cancers, 2021, 13, 5079. | 1.7 | 7 |
| 59 | Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53WT Uterine Leiomyosarcoma. Cancers, 2022, 14, 14. | 1.7 | 5 |
| 60 | Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours. International Journal of Oncology, 2018, 52, 967-977. | 1.4 | 4 |
| 61 | Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells. Oncotarget, 2016, 7, 74724-74733. | 0.8 | 4 |
| 62 | Highly Potent Clickable Probe for Cellular Imaging of MDM2 and Assessing Dynamic Responses to MDM2-p53 Inhibition. Bioconjugate Chemistry, 2018, 29, 2100-2106. | 1.8 | 3 |
| 63 | WIP1 Inhibition by GSK2830371 Potentiates HDM201 through Enhanced p53 Phosphorylation and Activation in Liver Adenocarcinoma Cells. Cancers, 2021, 13, 3876. | 1.7 | 3 |